Anti-PAD2 antibodies have been described in a subset of patients with RA characterized by milder articular damage, as well as less frequent and less severe extra-articular manifestations, especially ILD (84), whereas anti-PAD4 antibodies correlate with a more aggressive disease (111). The gene discussed is PADI4; the disease is interstitial lung disease.